Shares of United Therapeutics surged Monday after regulators approved the company's newest treatment for high blood pressure, Orenitram.
A Cowen and Co. analyst called the FDA's move a "surprise" because the FDA had refused to approve the drug twice before and United Therapeutics hasn't reported any additional data from clinical studies.